See more : Armor Minerals Inc. (RCZRF) Income Statement Analysis – Financial Results
Complete financial analysis of Sage Therapeutics, Inc. (SAGE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sage Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shandong Longhua New Material Co., Ltd. (301149.SZ) Income Statement Analysis – Financial Results
- BellRing Brands, Inc. (BRBR) Income Statement Analysis – Financial Results
- Xinxing Ductile Iron Pipes Co., Ltd. (000778.SZ) Income Statement Analysis – Financial Results
- Targa Exploration Corp. (TEX.CN) Income Statement Analysis – Financial Results
- Okabe Co., Ltd. (5959.T) Income Statement Analysis – Financial Results
Sage Therapeutics, Inc. (SAGE)
About Sage Therapeutics, Inc.
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 86.46M | 7.69M | 6.31M | 1.11B | 6.87M | 90.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 2.16M | 813.00K | 553.00K | 565.00K | 400.00K | 1.10M | 500.00K | 281.00K | 115.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 84.30M | 6.87M | 5.76M | 1.11B | 6.47M | 89.17M | -500.00K | -281.00K | -115.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 97.50% | 89.42% | 91.23% | 99.95% | 94.18% | 98.78% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 356.24M | 326.16M | 283.17M | 292.71M | 368.82M | 282.11M | 210.28M | 120.76M | 69.36M | 24.10M | 14.36M | 7.23M |
| General & Administrative | 274.52M | 227.70M | 183.50M | 196.95M | 345.78M | 201.40M | 62.88M | 39.41M | 25.29M | 9.71M | 3.38M | 2.40M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 44.60M | 11.18M | 5.27M | 3.08M | 0.00 | 0.00 | 0.00 |
| SG&A | 274.52M | 227.70M | 183.50M | 196.95M | 345.78M | 201.40M | 62.88M | 39.41M | 25.29M | 9.71M | 3.38M | 2.40M |
| Other Expenses | 33.39M | 15.00K | 134.00K | 250.00K | 82.00K | 22.00K | -64.00K | -35.00K | -23.00K | -9.00K | -3.00K | -1.00K |
| Operating Expenses | 664.15M | 553.86M | 466.66M | 489.67M | 714.59M | 483.51M | 273.16M | 160.16M | 94.65M | 33.81M | 18.28M | 9.63M |
| Cost & Expenses | 666.30M | 554.68M | 467.22M | 490.23M | 714.99M | 483.51M | 273.16M | 160.16M | 94.65M | 33.81M | 18.28M | 9.63M |
| Interest Income | 38.74M | 14.19M | 2.88M | 9.60M | 27.80M | 20.33M | 3.10M | 1.21M | 178.00K | 8.00K | 1.00K | 0.00 |
| Interest Expense | 0.00 | 14.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.39M | 1.12M | 4.18M | 2.63M | 2.28M | 1.10M | 500.00K | 281.00K | 115.00K | 51.00K | 47.00K | 44.00K |
| EBITDA | -545.07M | -545.87M | -456.73M | 626.60M | -705.84M | -392.10M | -269.62M | -160.16M | -94.65M | -33.81M | -18.23M | -9.59M |
| EBITDA Ratio | -630.47% | -7,116.69% | -7,306.74% | 58.49% | -10,310.48% | -435.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -579.85M | -546.99M | -460.91M | 596.23M | -708.12M | -393.24M | -273.16M | -160.16M | -94.65M | -33.81M | -18.28M | -9.63M |
| Operating Income Ratio | -670.69% | -7,116.69% | -7,306.74% | 53.51% | -10,310.48% | -435.61% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 38.36M | 14.21M | 3.02M | 9.85M | 27.89M | 20.36M | 3.04M | 1.18M | 155.00K | -1.00K | -2.00K | -1.00K |
| Income Before Tax | -541.49M | -532.78M | -457.89M | 606.07M | -680.24M | -372.88M | -270.12M | -158.99M | -94.50M | -33.81M | -18.28M | -9.63M |
| Income Before Tax Ratio | -626.32% | -6,931.88% | -7,258.91% | 54.40% | -9,904.46% | -413.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -29.52M | -7.07M | 15.52M | -30.09M | 20.36M | -3.63M | -1.49M | -293.00K | -59.00K | 2.00K | 0.00 |
| Net Income | -541.49M | -503.27M | -450.83M | 606.07M | -650.15M | -372.88M | -270.12M | -158.99M | -94.50M | -33.81M | -18.28M | -9.63M |
| Net Income Ratio | -626.32% | -6,547.84% | -7,146.91% | 54.40% | -9,466.38% | -413.06% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -9.05 | -8.49 | -7.68 | 11.66 | -12.79 | -8.08 | -7.09 | -4.75 | -3.40 | -1.57 | -1.09 | -0.57 |
| EPS Diluted | -9.05 | -8.49 | -7.68 | 11.43 | -12.79 | -8.08 | -7.09 | -4.75 | -3.40 | -1.57 | -0.73 | -0.39 |
| Weighted Avg Shares Out | 59.84M | 59.31M | 58.67M | 51.98M | 50.83M | 46.12M | 38.10M | 33.47M | 27.78M | 21.57M | 16.77M | 16.77M |
| Weighted Avg Shares Out (Dil) | 59.84M | 59.31M | 58.67M | 53.00M | 50.83M | 46.12M | 38.11M | 33.49M | 27.78M | 21.57M | 24.96M | 24.96M |
Sage Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
Investors who lost money on Sage Therapeutics, Inc. (SAGE) should contact The Gross Law Firm about pending Class Action - SAGE
Contact Levi & Korsinsky by October 28, 2024 Deadline to Join Class Action Against Sage Therapeutics, Inc.(SAGE)
Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
Sage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
Faruqi & Faruqi Reminds Sage Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - SAGE
Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE
Sage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
SAGE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Sage Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
Sage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE
Source: https://incomestatements.info
Category: Stock Reports